The landscape of sodium-glucose transporter (SGLT) inhibitors has seen significant advancements, particularly with the approval of numerous SGLT2 inhibitors for managing type 2 diabetes and its cardiovascular and renal complications. Here, SLC5A2 is linked to type 2 diabetes mellitus.